التفاصيل البيبلوغرافية
| العنوان: |
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. |
| المؤلفون: |
Morgan, Gareth J.1 gareth.morgan@icr.ac.ul, Davies, Faith E.1, Gregory, Walter M.2, Cocks, Kim2, Bell, Sue E.2, Szubert, Alex J.2, Navarro-Coy, Nuria2, Drayson, Mark T.3, Owen, Roger G.4, Feyler, Sylvia5, Ashcroft, A. John6, Ross, Fiona7, Byrne, Jennifer8, Roddie, Huw9, Rudin, Claudius10, Cook, Gordon4, Jackson, Graham H.11, Child, J. Anthony2 |
| المصدر: |
Lancet. 12/11/2010, Vol. 376 Issue 9757, p1989-1999. 11p. 2 Diagrams, 6 Charts, 1 Graph. |
| مصطلحات موضوعية: |
*DIPHOSPHONATES, *HEALTH outcome assessment, *MULTIPLE myeloma, *DRUG side effects, *PATIENTS |
| مصطلحات جغرافية: |
UNITED Kingdom |
| مستخلص: |
This article focuses on a study which examined whether bisphosphonates can affect clinical outcomes in patients with multiple myeloma. A number of patients from British centres served as subjects in this study. Results of the study showed that the zoledronic group experienced a significant improvement in overall survival compared to the clodronic acid group. The study also found that 27% of patients had a skeletal-related event prior to disease progression on zoledronic acid. Included is a table showing the profile of adverse events. |
| قاعدة البيانات: |
Academic Search Index |
